Virbac Past Earnings Performance

Past criteria checks 5/6

Virbac has been growing earnings at an average annual rate of 14%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 8.3% per year. Virbac's return on equity is 14.2%, and it has net margins of 10.5%.

Key information

14.0%

Earnings growth rate

14.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.3%
Return on equity14.2%
Net Margin10.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Virbac makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:V16 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,3391416050
31 Mar 241,2931315890
31 Dec 231,2471215730
30 Sep 231,2291205700
30 Jun 231,2101195680
31 Mar 231,2131215630
31 Dec 221,2161225570
30 Sep 221,1841205350
30 Jun 221,1511195130
31 Mar 221,1071165000
31 Dec 211,0641134870
30 Sep 211,0251374730
30 Jun 219851614590
31 Mar 219601484490
31 Dec 209341364390
30 Sep 209441044440
30 Jun 20953724480
31 Mar 20946624510
31 Dec 19938524540
30 Sep 19921434490
30 Jun 19903344450
31 Mar 19886274460
31 Dec 18869204460
30 Sep 1886284420
30 Jun 18854-44380
31 Mar 18858-34400
31 Dec 17862-34420
30 Sep 17871164440
30 Jun 17879354460
31 Mar 17876354490
31 Dec 16872354520
30 Sep 16861304590
30 Jun 16850264660
31 Mar 16851184630
31 Dec 1585394600
30 Sep 15846214410
30 Jun 15839324210
31 Mar 15806483980
31 Dec 14773643750
30 Sep 14752603660
30 Jun 14730563570
31 Mar 14733583560
31 Dec 13736613550

Quality Earnings: V16 has high quality earnings.

Growing Profit Margin: V16's current net profit margins (10.5%) are higher than last year (9.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: V16's earnings have grown by 14% per year over the past 5 years.

Accelerating Growth: V16's earnings growth over the past year (18.5%) exceeds its 5-year average (14% per year).

Earnings vs Industry: V16 earnings growth over the past year (18.5%) exceeded the Pharmaceuticals industry 1.5%.


Return on Equity

High ROE: V16's Return on Equity (14.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies